Literature DB >> 20185416

A pilot study to assess the efficacy of biofeedback-assisted relaxation training as an adjunct treatment for pediatric functional dyspepsia associated with duodenal eosinophilia.

Jennifer V Schurman1, Yelena P Wu, Paula Grayson, Craig A Friesen.   

Abstract

OBJECTIVES: To conduct a pilot study examining whether adding biofeedback-assisted relaxation training (BART) to medication treatment results in better clinical outcomes than medication treatment alone for children with functional dyspepsia (FD) associated with duodenal eosinophilia, a subgroup of children with recurrent abdominal pain.
METHODS: Twenty children were randomly assigned to receive a standardized medication treatment or medication plus 10 sessions of BART. Children and parents completed psychosocial functioning and quality of life measures at baseline, posttreatment, and 6 months. Children rated pain daily via PDA. Physicians provided biweekly assessments of clinical improvement.
RESULTS: Children receiving medication plus BART demonstrated better outcomes on pain intensity, duration of pain episodes, and clinical improvement than children receiving medication alone.
CONCLUSIONS: BART is a promising adjunctive treatment for pediatric FD associated with duodenal eosinophilia. Electronic daily diaries appear to be a useful approach to assessing changes in self-reported pain ratings in this population.

Entities:  

Mesh:

Year:  2010        PMID: 20185416     DOI: 10.1093/jpepsy/jsq010

Source DB:  PubMed          Journal:  J Pediatr Psychol        ISSN: 0146-8693


  12 in total

1.  Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest.

Authors:  Craig A Friesen; Jennifer V Schurman; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 2.  Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman; Jennifer M Colombo; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

Review 3.  Functional abdominal pain in childhood: background studies and recent research trends.

Authors:  Rona L Levy; Miranda A L van Tilburg
Journal:  Pain Res Manag       Date:  2012 Nov-Dec       Impact factor: 3.037

Review 4.  Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia.

Authors:  John M Rosen; Jose T Cocjin; Jennifer V Schurman; Jennifer M Colombo; Craig A Friesen
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

5.  [Functional gastrointestinal diseases].

Authors:  J Keller; P Layer
Journal:  Internist (Berl)       Date:  2013-11       Impact factor: 0.743

Review 6.  Implementing psychological therapies for gastrointestinal disorders in pediatrics.

Authors:  Bonney Reed; Jessica Buzenski; Miranda A L van Tilburg
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-08-18       Impact factor: 3.869

7.  How does one choose the appropriate pharmacotherapy for pediatric patients with functional dyspepsia?

Authors:  M Louai Manini; Michael Camilleri
Journal:  Expert Opin Pharmacother       Date:  2019-08-06       Impact factor: 3.889

Review 8.  Meditation for adults with haematological malignancies.

Authors:  Ines Salhofer; Andrea Will; Ina Monsef; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2016-02-03

9.  Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods.

Authors:  James P Franciosi; Kevin A Hommel; Charles W DeBrosse; Allison B Greenberg; Alexandria J Greenler; J Pablo Abonia; Marc E Rothenberg; James W Varni
Journal:  BMC Gastroenterol       Date:  2011-11-18       Impact factor: 3.067

Review 10.  Update on the Role of Allergy in Pediatric Functional Abdominal Pain Disorders: A Clinical Perspective.

Authors:  Craig Friesen; Jennifer Colombo; Jennifer Schurman
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.